Glioquell

GlioQuell is an Imperial College biopharmaceutical spinout company dedicated to developing technologies and therapeutics targeting cellular bioenergetics. Based on cutting-edge proprietary science, the company is discovering and developing novel therapeutics for treating refractory brain tumours and other diseases with significant medical and societal burden. Our innovative strategy is designed for targeted modulation of cellular metabolism to affect the viability of specific cell types, including highly proliferative malignant glioma cells. Our founding directors and advisors include leaders in mitochondrial biology and clinical medicine, with decades of experience in discovery and translation of novel findings into the clinic.